Cerebrolysin in the Management of Vascular Dementia

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Overview of Vascular Dementia

Vascular dementia (VaD) is recognized as the second most frequent form of dementia following Alzheimer’s disease (AD). It encompasses a spectrum of cognitive and functional impairments resulting from compromised cerebral blood flow. VaD falls within the broader category of vascular cognitive impairment (VCI), which includes all cognitive syndromes caused by cerebrovascular injury. These can arise from ischemic or hemorrhagic events or from hypoxic-ischemic brain damage of cardiovascular origin.

Although closely associated with stroke, VaD and post-stroke dementia (PSD) are not interchangeable. While many PSD cases demonstrate pathological features of VaD, some exhibit alternative dementing processes such as AD.

Despite its significant global burden, VaD has historically received less research attention compared to AD. Prevalence data reveal that the incidence of VaD doubles approximately every 5.3 years, whereas AD doubles every 4.5 years. In North America, AD accounts for 44–70% of dementia cases, while VaD contributes to 14.5–20%. UK studies report annual incidence rates of 1.59 per 1,000 person-years for AD and 0.99 per 1,000 for VaD. In China, prevalence in individuals aged ≥65 years was estimated at 1.5% between 2008–2009, compared to 3.21% for AD. In Japan, earlier studies suggested higher VaD prevalence than AD, but recent trends indicate a rise in AD without significant change in VaD incidence.

Challenges in Treatment

Despite its frequency, no definitive therapy has been established for VaD. Management strategies are typically categorized into prevention, symptomatic treatment, and disease-modifying approaches. Evidence for vascular risk factor modification or pharmacological prevention with agents such as antiplatelets or statins remains inconclusive. This unmet need has prompted ongoing investigation into therapeutic agents that could improve clinical outcomes.

Clinical Evaluation of Cerebrolysin

A multicenter, randomized, double-blind, placebo-controlled trial examined the efficacy and safety of Cerebrolysin in patients with VaD. Conducted in line with the Declaration of Helsinki, the study enrolled 242 patients, randomized equally into placebo (n=121) and Cerebrolysin (n=121) groups. A total of 217 patients (89.7%) completed the 24-week trial.

Participants received 20 ml intravenous Cerebrolysin once daily during two treatment cycles, in addition to standard therapy with acetylsalicylic acid. The primary endpoints were changes in the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-cog+) and Clinical Global Impression of Change (CIBIC+).

At week 24, the Cerebrolysin group demonstrated statistically significant improvements:

• Cognition (ADAS-cog+): LS mean difference of –6.17 versus placebo (p<0.0001).
• Overall clinical function (CIBIC+): mean difference of –0.84 versus placebo (p<0.0001).

Responder analyses confirmed superiority of Cerebrolysin:

• ADAS-cog+ improvement ≥4 points: 82.1% vs. 52.2%.
• CIBIC+ score <4: 75.2% vs. 37.4%.
• Combined response (ADAS-cog+ and CIBIC+): 67.5% vs. 27.0%.

Odds ratios favored Cerebrolysin for both CIBIC+ (5.081, p<0.05) and combined endpoints (5.633, p<0.05). Additional benefits were observed in Mini-Mental State Examination (MMSE), functional outcomes (ADCS-ADL), and executive function assessments (Trail-Making Test, Clock-Drawing Test).

Proposed Mechanisms of Action

Experimental evidence supports several mechanisms through which Cerebrolysin may exert neuroprotective and neurotrophic effects:

1. Amyloid regulation: Reduction in amyloid plaque formation via modulation of amyloid precursor protein (APP).
2. Anti-apoptotic activity: Inhibition of calpain and caspase-3 pathways, alongside modulation of Bcl-2 and Bax, preventing neuronal apoptosis.
3. Synaptic plasticity enhancement: Structural improvements in dendritic morphology, increased dendritic length and spine density, and upregulation of synaptic proteins.
4. Neurogenesis support: Promotion of progenitor cell survival, proliferation, and differentiation, contributing to neuronal regeneration.

Conclusion

Cerebrolysin demonstrated significant clinical benefit in patients with vascular dementia, improving both cognition and functional outcomes over a six-month period. The treatment was well tolerated and safe, with evidence supporting its neuroprotective and restorative mechanisms. These findings suggest Cerebrolysin as a promising adjunctive therapy in the management of vascular dementia.

REFERENCES

1. Guekht, A. B., Moessler, H., Novak, P. H., Gusev, E. I., & Cerebrolysin Investigators (2011). Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 20(4), 310–318. https://doi.org/10.1016/j.jstrokecerebrovasdis.2010.01.012
2. Muresanu, D. F., Alvarez, X. A., Moessler, H., Novak, P. H., Stan, A., Buzoianu, A., Bajenaru, O., & Popescu, B. O. (2010). Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study. Journal of the neurological sciences, 299(1-2), 179–183. https://doi.org/10.1016/j.jns.2010.08.040

Allegri, R. F., & Guekht, A. (2012). Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia. Drugs of today (Barcelona, Spain : 1998), 48 Suppl A, 25–41. https://doi.org/10.1358/dot.2012.48(Suppl.A).1739721